What is Syndax Pharmaceuticals's R&D?

Syndax Pharmaceuticals (SNDX) reported R&D of $58.85M in Q1 2026.

How has Syndax Pharmaceuticals's R&D changed year-over-year?

Syndax Pharmaceuticals's R&D decreased by 4.5% year-over-year, from $61.64M to $58.85M.

What is the long-term trend for Syndax Pharmaceuticals's R&D?

Over 4 years (2021 to 2025), Syndax Pharmaceuticals's R&D has grown at a 30.9% compound annual growth rate (CAGR), from $88.25M to $258.78M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Syndax Pharmaceuticals SNDX R&D

R&D at other companies

BiogenBIIB

$539M+24.2%

IncyteINCY

$515.9M+18.0%

SELLAS Life Sciences Group, Inc.SLS

$5.13M+60.0%

ArriVent BioPharma, Inc.AVBP

$37.62M-38.6%

Viridian Therapeutics, Inc.VRDN

$77.63M+1.0%

Nuvation BioNUVB

$35.05M+42.5%

Other financials

Income statement

See full

Revenue$64.9M+224%

Operating income-$34.2M+59.2%

Net income-$42.7M+49.7%

EPS (diluted)-$0.48+51.0%

Balance sheet

See full

Cash & equivalents$130.9M-15.0%

Total debt$350.5M+4.2%

Total equity$41.6M-80.6%

Total assets$472.7M-26.2%

Cash flow

See full

Operating cash flow-$50.3M+47.1%

CapEx$46.8K—

Free cash flow-$80.8M-17.6%

Valuation

See full

Market cap$1.74B+95.0%

Enterprise value$1.96B+84.0%

P/S8×-12.4×

Profitability

See full

Operating margin-102.8%-47.8pp

Net margin-111.9%-51.5pp

FCF margin-187.2%-85.4pp

Returns & leverage

See full

Return on equity-189.5%-8,509pp

Debt / equity8.4×+6.9×

Current ratio5.5×-0.3×

Where this comes from

Reported directly by Syndax Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Syndax Pharmaceuticals's r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Syndax Pharmaceuticals's R&D?: Syndax Pharmaceuticals (SNDX) reported R&D of $58.85M in Q1 2026.
How has Syndax Pharmaceuticals's R&D changed year-over-year?: Syndax Pharmaceuticals's R&D decreased by 4.5% year-over-year, from $61.64M to $58.85M.
What is the long-term trend for Syndax Pharmaceuticals's R&D?: Over 4 years (2021 to 2025), Syndax Pharmaceuticals's R&D has grown at a 30.9% compound annual growth rate (CAGR), from $88.25M to $258.78M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.